President & Chief Development Officer, Metabolic Disorders and NeurologyMelissa Rhodes is President & Chief Development Officer of Metabolic Diseases and Neurology at Kriya. Melissa joined Kriya from Aerami Therapeutics, a company focused on inhaled biologic therapies where she was the Chief Development Officer. Prior to Aerami, Melissa was the Chief Development Officer at Altavant Sciences, a respiratory rare disease company. She also served as Senior Vice President at Roivant Sciences, where she built and led a team of scientists conducting nonclinical research for multiple Roivant subsidiary companies. Melissa spent almost ten years in R&D at GlaxoSmithKline. She started her career in drug development at an oncology-focused biotech university spin-out. Melissa received her PhD in pharmacology and toxicology from Duke University Medical Center. She completed a postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences and is a diplomate of the American Board of Toxicology.